Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Shareholders Challenge Perrigo's Defense Against Mylan Offer Two Years Earlier

Nov 07 2017

• By Eileen Francis

Economics graph

Related Content

Omega Marks The Alpha Of Perrigo’s OTC Brand Play

Mar 19 2015

Perrigo Stands Alone At Top OF OTC Private Label Market, In Hunt For More Deals

Nov 16 2015

Perrigo’s Outgoing CEO Advocates OTC Switches, Starting With Statins

Aug 11 2017

Perrigo Trims Workforce, Ships Tysabri License, Stays European Course

Mar 01 2017

Starboard Agreement Tilts Perrigo Toward Rx Generics Sale

Feb 07 2017

Perrigo CEO Takes Faith In Rx Generics Business To Exit Door With Him

Jun 06 2017

Related Companies

Perrigo Company PLC

Viatris Inc.

Omega Pharma NV

Additional Topics

United States International Regulation Legal Issues Trade Policy OTC Drugs Consumer

More from Legal & IP

More from Pink Sheet

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.